CORRESP Filing
Medicus Pharma Ltd.
Date: Jan. 30, 2026 · CIK: 0001997296 · Accession: 0001062993-26-000507
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-293091
Letter
Medicus Pharma Ltd.: CORRESP - Filed by newsfilecorp.com
Medicus Pharma Ltd. 300 Conshohocken State Road, Suite 200 Conshohocken, PA 19428 January 30, 2026 VIA EDGAR Division of Corporation Finance Office of Life Sciences Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: Medicus Pharma Ltd. Registration Statement on Form S-3 (No. 333-293091) Filed January 30, 2026 Dear Ladies and Gentlemen: Pursuant to Rule 461 of the Securities Act of 1933, as amended, we hereby request that the effective date of the Registration Statement on Form S-3, File No. 333-293091, as amended (the " Registration Statement "), of Medicus Pharma Ltd. (the " Company ") be accelerated to February 3, 2026 at 5:00 PM ET or as soon thereafter as may be practicable. Please contact Christopher J. Cummings of Paul, Weiss, Rifkind, Wharton & Garrison LLP, special counsel to the Company, at (212) 373-3434, as soon as the Registration Statement has been declared effective, or if you have any other questions or concerns regarding this matter. ***** Very truly yours, By: /s/ Raza Bokhari Name: Dr. Raza Bokhari Title: Executive Chairman and Chief Executive Officer
Show Raw Text
CORRESP 1 filename1.htm Medicus Pharma Ltd.: CORRESP - Filed by newsfilecorp.com Medicus Pharma Ltd. 300 Conshohocken State Road, Suite 200 Conshohocken, PA 19428 January 30, 2026 VIA EDGAR Division of Corporation Finance Office of Life Sciences Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: Medicus Pharma Ltd. Registration Statement on Form S-3 (No. 333-293091) Filed January 30, 2026 Dear Ladies and Gentlemen: Pursuant to Rule 461 of the Securities Act of 1933, as amended, we hereby request that the effective date of the Registration Statement on Form S-3, File No. 333-293091, as amended (the " Registration Statement "), of Medicus Pharma Ltd. (the " Company ") be accelerated to February 3, 2026 at 5:00 PM ET or as soon thereafter as may be practicable. Please contact Christopher J. Cummings of Paul, Weiss, Rifkind, Wharton & Garrison LLP, special counsel to the Company, at (212) 373-3434, as soon as the Registration Statement has been declared effective, or if you have any other questions or concerns regarding this matter. ***** Very truly yours, By: /s/ Raza Bokhari Name: Dr. Raza Bokhari Title: Executive Chairman and Chief Executive Officer